| Emerging therapeutic opportunities for integrin inhibitors RJ Slack, SJF Macdonald, JA Roper, RG Jenkins, RJD Hatley Nature Reviews Drug Discovery 21 (1), 60-78, 2022 | 374 | 2022 |
| Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis N Hirani, AC MacKinnon, L Nicol, P Ford, H Schambye, A Pedersen, ... European Respiratory Journal 57 (5), 2021 | 185 | 2021 |
| In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action RJ Slack, VJ Barrett, VS Morrison, RG Sturton, AJ Emmons, AJ Ford, ... The Journal of pharmacology and experimental therapeutics 344 (1), 218-230, 2013 | 142 | 2013 |
| The therapeutic potential of galectin-3 inhibition in fibrotic disease RJ Slack, R Mills, AC Mackinnon The International Journal of Biochemistry & Cell Biology 130, 105881, 2021 | 128 | 2021 |
| An αv‐RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities RJD Hatley, SJF Macdonald, RJ Slack, J Le, SB Ludbrook, PT Lukey Angewandte Chemie International Edition 57 (13), 3298-3321, 2018 | 128 | 2018 |
| Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis AE John, RH Graves, KT Pun, G Vitulli, EJ Forty, PF Mercer, JL Morrell, ... Nature communications 11 (1), 4659, 2020 | 99 | 2020 |
| Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases M Salmon, MA Luttmann, JJ Foley, PT Buckley, DB Schmidt, M Burman, ... The Journal of pharmacology and experimental therapeutics 345 (2), 260-270, 2013 | 80 | 2013 |
| Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants CH Maden, D Fairman, M Chalker, MJ Costa, WA Fahy, N Garman, ... European journal of clinical pharmacology 74, 701-709, 2018 | 62 | 2018 |
| Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists L Ajram, M Begg, R Slack, J Cryan, D Hall, S Hodgson, A Ford, A Barnes, ... European journal of pharmacology 729, 75-85, 2014 | 56 | 2014 |
| Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease FR Zetterberg, A MacKinnon, T Brimert, L Gravelle, RE Johnsson, ... Journal of Medicinal Chemistry 65 (19), 12626-12638, 2022 | 55 | 2022 |
| A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled … TM Maher, JK Simpson, JC Porter, FJ Wilson, R Chan, R Eames, Y Cui, ... Respiratory Research 21, 1-9, 2020 | 51 | 2020 |
| Pharmacological characterization of GSK1004723, a novel, long‐acting antagonist at histamine H1 and H3 receptors RJ Slack, LJ Russell, DA Hall, MA Luttmann, AJ Ford, KA Saunders, ... British journal of pharmacology 164 (6), 1627-1641, 2011 | 50 | 2011 |
| Synthesis and structure–activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists PA Procopiou, JW Barrett, NP Barton, M Begg, D Clapham, RCB Copley, ... Journal of Medicinal Chemistry 56 (5), 1946-1960, 2013 | 46 | 2013 |
| Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC … RJ Slack, DA Hall British journal of pharmacology 166 (6), 1774-1792, 2012 | 44 | 2012 |
| The Discovery of Phthalazinone-Based Human H1 and H3 Single-Ligand Antagonists Suitable for Intranasal Administration for the Treatment of Allergic Rhinitis PA Procopiou, C Browning, JM Buckley, KL Clark, L Fechner, PM Gore, ... Journal of Medicinal Chemistry 54 (7), 2183-2195, 2011 | 43 | 2011 |
| Discovery of (S)-3-(3-(3, 5-Dimethyl-1 H-pyrazol-1-yl) phenyl)-4-((R)-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl) butanoic Acid, a Nonpeptidic … PA Procopiou, NA Anderson, J Barrett, TN Barrett, MHJ Crawford, ... Journal of Medicinal Chemistry 61 (18), 8417-8443, 2018 | 40 | 2018 |
| Pharmacological characterization of the αvβ6 integrin binding and internalization kinetics of the foot-and-mouth disease virus derived peptide A20FMDV2 RJ Slack, M Hafeji, R Rogers, SB Ludbrook, JF Marshall, DJ Flint, S Pyne, ... Pharmacology 97 (3-4), 114-125, 2016 | 39 | 2016 |
| An inhaled galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib/IIa randomized controlled clinical trial (DEFINE) EE Gaughan, TM Quinn, A Mills, AM Bruce, J Antonelli, AC MacKinnon, ... American Journal of Respiratory and Critical Care Medicine 207 (2), 138-149, 2023 | 32 | 2023 |
| Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand ER Hall, LI Bibby, RJ Slack Biochemical Pharmacology 117, 88-96, 2016 | 29 | 2016 |
| Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation DC Humphries, R Mills, C Boz, BJ McHugh, N Hirani, AG Rossi, ... Frontiers in pharmacology 13, 949264, 2022 | 25 | 2022 |